N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide induces antidepressant-like effect in mice: involvement of the serotonergic system
ConclusionThis study pointed a new compound with antidepressant-like effect, and it could be considered for the development of new antidepressants. (Source: Psychopharmacology)
Source: Psychopharmacology - April 18, 2024 Category: Psychiatry Source Type: research
Effects of oral administration of ondansetron, a 5-HT3 receptor antagonist, on anxiety-related behaviors and colonic hypercontractility in repeated stress-induced mice
This study aimed to investigate the effects of ondansetron, a 5-HT3 receptor antagonist, on locomotor activity, anxiety-related behaviors, and colonic functions in repeated water avoidance stress. (Source: Autonomic Neuroscience: Basic and Clinical)
Source: Autonomic Neuroscience: Basic and Clinical - April 17, 2024 Category: Neuroscience Authors: Affan Waemong, Sarunnuch Sattayachiti, Dania Cheaha, Nipaporn Konthapakdee Source Type: research
Single intravenous dose ondansetron induces QT prolongation in adult emergency department patients: a prospective observational study
ConclusionsOur study demonstrates the predictive capacity of QT0, QTc0, and ondansetron dosage in forecasting QTc60 prolongation (> 480 msec) post-ondansetron administration. These findings advocate for their incorporation into clinical protocols to enhance safety monitoring in adult ED patients. (Source: International Journal of Emergency Medicine)
Source: International Journal of Emergency Medicine - April 2, 2024 Category: Emergency Medicine Source Type: research
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants
Antimicrob Agents Chemother. 2024 Mar 29:e0145523. doi: 10.1128/aac.01455-23. Online ahead of print.ABSTRACTFosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment. Data from two phase 1, placebo-controlled studies [IV-oral switch (study 1) and multiple IV doses (study 2)] evaluating FMGX tolerability, and pharmacokinetics (PK) are presented. Healthy adults (study 1: 18-65 years; study 2: 18-55 years) were eligible (randomized 3:1 to FMGX: placebo). Eleven participants completed study 1. In study...
Source: Antimicrobial Agents and Chemotherapy - March 29, 2024 Category: Microbiology Authors: Michael R Hodges Susan Hazel William G Kramer Ewoud-Jan van Hoogdalem Sjoerd van Marle Margaret Tawadrous Abhijeet Jakate Source Type: research
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants
Antimicrob Agents Chemother. 2024 Mar 29:e0145523. doi: 10.1128/aac.01455-23. Online ahead of print.ABSTRACTFosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment. Data from two phase 1, placebo-controlled studies [IV-oral switch (study 1) and multiple IV doses (study 2)] evaluating FMGX tolerability, and pharmacokinetics (PK) are presented. Healthy adults (study 1: 18-65 years; study 2: 18-55 years) were eligible (randomized 3:1 to FMGX: placebo). Eleven participants completed study 1. In study...
Source: Antimicrobial Agents and Chemotherapy - March 29, 2024 Category: Microbiology Authors: Michael R Hodges Susan Hazel William G Kramer Ewoud-Jan van Hoogdalem Sjoerd van Marle Margaret Tawadrous Abhijeet Jakate Source Type: research
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants
Antimicrob Agents Chemother. 2024 Mar 29:e0145523. doi: 10.1128/aac.01455-23. Online ahead of print.ABSTRACTFosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment. Data from two phase 1, placebo-controlled studies [IV-oral switch (study 1) and multiple IV doses (study 2)] evaluating FMGX tolerability, and pharmacokinetics (PK) are presented. Healthy adults (study 1: 18-65 years; study 2: 18-55 years) were eligible (randomized 3:1 to FMGX: placebo). Eleven participants completed study 1. In study...
Source: Antimicrobial Agents and Chemotherapy - March 29, 2024 Category: Microbiology Authors: Michael R Hodges Susan Hazel William G Kramer Ewoud-Jan van Hoogdalem Sjoerd van Marle Margaret Tawadrous Abhijeet Jakate Source Type: research
Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment
CONCLUSIONS: Low-dose AD04 has the potential to be a safe treatment option for subjects with AUD and ALD, indicating the need for an RCT for this specific cohort. Such a trial would pave the way for the design of a precision treatment for combined AUD with ALD.PMID:38521730 | DOI:10.1016/j.ejim.2024.03.017 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - March 23, 2024 Category: Internal Medicine Authors: Giovanni Addolorato Hannu Alho Paula Bresciani M De Andrade Otto Michael Lesch Lei Liu Bankole Johnson Source Type: research
Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment
CONCLUSIONS: Low-dose AD04 has the potential to be a safe treatment option for subjects with AUD and ALD, indicating the need for an RCT for this specific cohort. Such a trial would pave the way for the design of a precision treatment for combined AUD with ALD.PMID:38521730 | DOI:10.1016/j.ejim.2024.03.017 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - March 23, 2024 Category: Internal Medicine Authors: Giovanni Addolorato Hannu Alho Paula Bresciani M De Andrade Otto Michael Lesch Lei Liu Bankole Johnson Source Type: research
Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment
CONCLUSIONS: Low-dose AD04 has the potential to be a safe treatment option for subjects with AUD and ALD, indicating the need for an RCT for this specific cohort. Such a trial would pave the way for the design of a precision treatment for combined AUD with ALD.PMID:38521730 | DOI:10.1016/j.ejim.2024.03.017 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - March 23, 2024 Category: Internal Medicine Authors: Giovanni Addolorato Hannu Alho Paula Bresciani M De Andrade Otto Michael Lesch Lei Liu Bankole Johnson Source Type: research
Fatal coinfection of blastocystosis and intestinal trichomoniasis in a rhesus macaque (Macaca mulatta)
AbstractA 3-year-old male rhesus macaque was presented at Referral Veterinary Polyclinic-Teaching Veterinary Clinical Complex, with a chief complaint of chronic diarrhoea and swelling of dependent body parts. The patient's history indicates that the monkey had been experiencing diarrhoea for the past month, with 2 –3 episodes of vomiting in the last 2 days. Additionally, oedema has developed within the last 2 weeks. The clinical examination findings revealed dullness and depression, the mucus membrane appeared pale, with a temperature-102.1 °F, a respiration rate-28/min, and a heart rate-92/min. The cap illary refill...
Source: Journal of Parasitic Diseases - March 19, 2024 Category: Parasitology Source Type: research
Unveiling the antinociceptive mechanisms of Methyl-2-(4-chloro-phenyl)-5-benzoxazoleacetate: insights from nociceptive assays in mice
CONCLUSIONS: MCBA-induced antinociception involves modulation of glutamatergic-, TRVP1 receptors- and PKC-signaling pathways. It impacts adenosinergic, alpha-2 adrenergic, and cholinergic receptors and opens ATP-sensitive potassium channels.PMID:38497888 | DOI:10.26355/eurrev_202403_35620 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - March 18, 2024 Category: Drugs & Pharmacology Authors: Q Jarrar R Ayoub Y Jarrar H Jaffal K W Goh L C Ming S Moshawih A Sirhan Source Type: research
Unveiling the antinociceptive mechanisms of Methyl-2-(4-chloro-phenyl)-5-benzoxazoleacetate: insights from nociceptive assays in mice
CONCLUSIONS: MCBA-induced antinociception involves modulation of glutamatergic-, TRVP1 receptors- and PKC-signaling pathways. It impacts adenosinergic, alpha-2 adrenergic, and cholinergic receptors and opens ATP-sensitive potassium channels.PMID:38497888 | DOI:10.26355/eurrev_202403_35620 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: Q Jarrar R Ayoub Y Jarrar H Jaffal K W Goh L C Ming S Moshawih A Sirhan Source Type: research
Unveiling the antinociceptive mechanisms of Methyl-2-(4-chloro-phenyl)-5-benzoxazoleacetate: insights from nociceptive assays in mice
CONCLUSIONS: MCBA-induced antinociception involves modulation of glutamatergic-, TRVP1 receptors- and PKC-signaling pathways. It impacts adenosinergic, alpha-2 adrenergic, and cholinergic receptors and opens ATP-sensitive potassium channels.PMID:38497888 | DOI:10.26355/eurrev_202403_35620 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - March 18, 2024 Category: Drugs & Pharmacology Authors: Q Jarrar R Ayoub Y Jarrar H Jaffal K W Goh L C Ming S Moshawih A Sirhan Source Type: research
Unveiling the antinociceptive mechanisms of Methyl-2-(4-chloro-phenyl)-5-benzoxazoleacetate: insights from nociceptive assays in mice
CONCLUSIONS: MCBA-induced antinociception involves modulation of glutamatergic-, TRVP1 receptors- and PKC-signaling pathways. It impacts adenosinergic, alpha-2 adrenergic, and cholinergic receptors and opens ATP-sensitive potassium channels.PMID:38497888 | DOI:10.26355/eurrev_202403_35620 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: Q Jarrar R Ayoub Y Jarrar H Jaffal K W Goh L C Ming S Moshawih A Sirhan Source Type: research
